<DOC>
	<DOCNO>NCT02543918</DOCNO>
	<brief_summary>The purpose study compare body 's immune response vaccine give alone versus vaccine give along study drug call ixekizumab . The vaccine protect pneumonia tetanus . This study last 6 week follow-up 12 week .</brief_summary>
	<brief_title>A Study Immune Response Vaccines Ixekizumab ( LY2439821 ) Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy male female without compromise immune system Have body mass Index 18 32 kilogram per square meter ( kg/mÂ² ) Previously complete withdrawn ixekizumab study study investigate interleukin17 ( IL17 ) antagonist Have participate , within last 30 day , clinical trial involve investigational product . If previous investigational product long halflife , 3 month 5 halflives ( whichever longer ) pass Have know allergy hypersensitivity biologic therapy Past vaccination allergy Arthustype hypersensitivity Received tetanus toxoidcontaining vaccine within last 5 year Severe allergic reaction Boostrix Allergic latex Have immunize pneumococcal vaccine Known hypogammaglobulinemia History GuillainBarre Syndrome Active infectious disease Had live vaccination within 1 year prior screening , intend live vaccination course study Evidence significant uncontrolled neuropsychiatric disorder Have score 3 Item 12 Quick Inventory Depressive SymptomatologySelf Report ( 16 Items ) screen Evidence Human Immunodeficiency Virus infection , Hepatitis C , B Had symptomatic herpes zoster within 3 month screen Women lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>